The current methylation analysis in tissue and blood showed hypermethylation of both cancer biomarkers in patients with PCa compared to patients without PCa, with methylation status of SHOX2 and SEPT9 allowing differentiation between healthy and diseased patients and determination of tumor burden and aggressiveness. This evidence concerns the gene SHOX2 and neoplasm.